Infections Related to Biologics-1판

Cover image
Title page
Table of Contents
Copyright
Contributors
Infectious Disease Clinics of North America
Preface
Infections Related to Biologics: Agents Targeting B Cells
Key points
Introduction
Specific agents targeting B cells or plasma cells
Summary
Risk of Serious Infection Associated with Agents that Target T-Cell Activation and Interleukin-17 and Interleukin-23
Cytokines
Key points
Introduction
Inhibitors of the interaction between antigen presenting or dendritic cells and CD4 T lymphocytes
Interleukin-17 and interleukin-23 inhibitors
Direct T-cell Inhibition and Agents Targeting T-cell Migration and Chemotaxis
Key points
Introduction
Interleukin-2 receptor inhibitors: basiliximab and daclizumab
Anti-CD52 agents: alemtuzumab
Antiintegrin agents: natalizumab, vedolizumab, and efalizumab
Infectious Implications of Interleukin-1, Interleukin-6, and T Helper Type 2 Inhibition
Key points
Introduction
Interleukin-6
Interleukin-1
T helper type 2
Summary
Infectious Complications of Immune Checkpoint Inhibitors
Key points
Introduction
Mechanism of action of checkpoint inhibitors
Role of targeting the cytotoxic T-lymphocyte associated protein4 and programmed cell death protein 1/programmed cell
death protein 1 ligand pathways in host defense against infection
The spectrum of infectious complications during checkpoint inhibitors therapy
Specific infectious complications that may relate to checkpoint inhibitors
Complications of checkpoint inhibitors–induced neutropenia
Summary
Disclosure
Infectious Complications of Tyrosine Kinase Inhibitors in Hematological Malignancies
Key points
Introduction
BCR-ABL
Bruton tyrosine kinase
Other tyrosine kinase inhibitors
Summary
Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors
Key points
Introduction
ErbB receptor tyrosine kinase–targeted agents: erlotinib (Tarceva), gefitinib (Iressa), afatinib (Giotrif), osimertinib
(Tagrisso), lapatinib (Tyverb), and neratinib (Nerlynx)
Anaplastic lymphoma kinase inhibitors: crizotinib (Xalkori), ceritinib (Zykadia), alectinib (Alecensa), brigatinib
(Alunbrig), lorlatinib (Lorbrena)
Mammalian target of rapamycin inhibitors: rapamycin/sirolimus (Rapamune), temsirolimus (Torisel), everolimus (Afinitor,
Votubia)
BRAF and MEK kinase inhibitors: vemurafenib (Zelboraf), dabrafenib (Tafinlar), encorafenib (Braftovi), trametinib
(Mekinist), cobimetinib (Cotellic), and binimetinib (Mektovi)
Agents targeting vascular endothelial growth factor receptor family tyrosine kinase and other angiogenic pathways:
axitinib (Inlyta), cabozantinib (Cometriq, Cabometyx), lenvatinib (Lenvima), pazopanib (Votrient), regorafenib
(Stivarga), sorafenib (Nexavar), sunitinib (Sutent)
Summary
Infectious Risks Associated with Biologics Targeting Janus Kinase-Signal Transducer and Activator of Transcription
Signaling and Complement Pathway for Inflammatory Diseases
Key points
Introduction
Summary
Herpesvirus Infections Potentiated by Biologics
Key points
Introduction
Biology and pathogenesis of herpesviruses
Herpesvirus infections with biologics
Agents Targeting B Cells
Agents Targeting T-cell Activation
Direct T-cell Inhibitors
Interleukin (IL)-4, IL-5, and IL-6 Inhibitors
Conclusion
Tyrosine Kinase (TK) Inhibitors for Hematologic Malignancies
Targeting Janus Kinase (JAK)–STAT Signaling and Complement Pathway for Inflammatory Diseases
Miscellaneous
Prevention of herpesvirus infection
Summary
Hepatitis B Virus Reactivation Potentiated by Biologics
Key points
Introduction
General information on hepatitis B virus reactivation
Hepatitis B virus reactivation for hepatitis B surface antigen–positive patients treated with biologics
Hepatitis B virus reactivation for hepatitis B surface antigen–negative/anti–hepatitis B core–positive patients treated
with biologics
Screening, management, and prophylaxis for hepatitis B virus reactivation
Special population coinfected with hepatitis C virus or human immunodeficiency virus
Summary
JC Polyomavirus Infection Potentiated by Biologics
Key points
Introduction
Biology of JC polyomavirus
Pathogenesis of JC polyomavirus encephalopathy with biologics
Prevention and treatment of JC polyomavirus encephalopathy
Summary
Disclosure
Fungal Infections Potentiated by Biologics
Key points
Introduction
Tumor necrosis factor-α inhibitors
Ibrutinib and tyrosine kinase inhibitors
Monoclonal checkpoint inhibitors
Interleukin inhibitors
Cluster of differentiation inhibitors
Agents targeting T-cell activation
Other monoclonal antibodies
Summary
Mycobacterial Infections Potentiated by Biologics
Key points
Introduction
Tuberculosis
Nontuberculous mycobacteria
Summary
Vaccinations and Biologics
Key points
Introduction
Methods
Hepatitis B vaccine
Influenza vaccine
Measles, mumps, and rubella vaccine
Pneumococcal vaccine
Herpes zoster vaccine
Tetanus toxoid vaccine
Human papilloma virus vaccination
Yellow fever vaccine
Summary